Literature DB >> 21911717

Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics.

Edoardo Colzani1, Annelie Liljegren, Anna L V Johansson, Jan Adolfsson, Henrik Hellborg, Per F L Hall, Kamila Czene.   

Abstract

PURPOSE: The proportion of women living with a diagnosis of breast cancer in developed countries is increasing. Because breast cancer-specific deaths decrease with time since diagnosis, it is important to assess the burden of other causes of death in women diagnosed with breast cancer.
METHODS: Different causes of death within 10 years from diagnosis were assessed in 12,850 women younger than 75 years of age with stage 1 to 3 breast cancer diagnosed in Stockholm and Gotland regions 1990 to 2006. Flexible parametric survival models were used to estimate hazard ratios over time since diagnosis by tumor characteristics and age at diagnosis.
RESULTS: The proportion of deaths attributed to breast cancer ranged from 95.0% among women younger than age 45 years at diagnosis to 44.5% among women age 65 to 74 years. The proportions of circulatory system-specific deaths and deaths resulting from other causes increased with older age at diagnosis. Patients with one to three positive lymph nodes were more likely to die as a result of breast cancer during the first 10 years of follow-up compared with women without positive lymph nodes. Women with estrogen receptor (ER) -positive tumors had the same risk of dying as a result of breast cancer 5 years after diagnosis compared with women with ER-negative tumors.
CONCLUSION: Lymph node negativity is an important long-term predictor of more favorable prognosis. The nature of the relationship between ER status and risk of dying as a result of breast cancer after 5 years of follow-up requires further investigation. Circulatory system diseases are an important cause of death, especially in women diagnosed with breast cancer at an older age.

Entities:  

Mesh:

Year:  2011        PMID: 21911717     DOI: 10.1200/JCO.2010.32.6462

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  72 in total

Review 1.  Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms.

Authors:  Susan G Lakoski; Lee W Jones; Ronald J Krone; Phyllis K Stein; Jessica M Scott
Journal:  Am Heart J       Date:  2015-05-28       Impact factor: 4.749

2.  Neighborhood socioeconomic deprivation, tumor subtypes, and causes of death after non-metastatic invasive breast cancer diagnosis: a multilevel competing-risk analysis.

Authors:  Min Lian; Maria Pérez; Ying Liu; Mario Schootman; Ann Frisse; Ellen Foldes; Donna B Jeffe
Journal:  Breast Cancer Res Treat       Date:  2014-09-19       Impact factor: 4.872

Review 3.  Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis.

Authors:  Mary C Playdon; Michael B Bracken; Tara B Sanft; Jennifer A Ligibel; Maura Harrigan; Melinda L Irwin
Journal:  J Natl Cancer Inst       Date:  2015-09-30       Impact factor: 13.506

4.  Identification of breast cancer prognostic modules based on weighted protein-protein interaction networks.

Authors:  Wan Li; Xue Bai; Erqiang Hu; Hao Huang; Yiran Li; Yuehan He; Junjie Lv; Lina Chen; Weiming He
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

5.  Causes of death among cancer patients.

Authors:  N G Zaorsky; T M Churilla; B L Egleston; S G Fisher; J A Ridge; E M Horwitz; J E Meyer
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

6.  Cardiac autonomic modulation impairments in advanced breast cancer patients.

Authors:  Claudia Arab; Luiz Carlos Marques Vanderlei; Laércio da Silva Paiva; Kyle Levi Fulghum; Carlos Elias Fristachi; Afonso Celso Pinto Nazario; Simone Elias; Luiz Henrique Gebrim; Celso Ferreira Filho; Yori Gidron; Celso Ferreira
Journal:  Clin Res Cardiol       Date:  2018-05-02       Impact factor: 5.460

7.  Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.

Authors:  Mohamed Ismail Nounou; Chris E Adkins; Evelina Rubinchik; Tori B Terrell-Hall; Mohamed Afroz; Tim Vitalis; Reinhard Gabathuler; Mei Mei Tian; Paul R Lockman
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

8.  Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.

Authors:  Jingmei Li; Keith Humphreys; Louise Eriksson; Gustaf Edgren; Kamila Czene; Per Hall
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

9.  Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients.

Authors:  Zhong Ye; Juan P Palazzo; Liz Lin; Yinzhi Lai; Fran Guiles; Ronald E Myers; Jin Han; Jinliang Xing; Hushan Yang
Journal:  J Gastroenterol Hepatol       Date:  2013-09       Impact factor: 4.029

10.  Lower rate-pressure product during submaximal walking: a link to fatigue improvement following a physical activity intervention among breast cancer survivors.

Authors:  Stephen J Carter; Gary R Hunter; Edward McAuley; Kerry S Courneya; Philip M Anton; Laura Q Rogers
Journal:  J Cancer Surviv       Date:  2016-04-09       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.